Business Context and Reporting Period
This Form 6-K filing by Globavend Holdings Ltd, a Cayman Islands exempted company, covers the month of June 2025. The report details the pricing and closing of a $15 million best efforts public offering of units and pre-funded units.
Key Financial Metrics
- Gross Proceeds: $15 million from the sale of 5,645,997 Ordinary Units and 16,093,133 Pre-Funded Units.
- Offering Prices: $0.69 per Ordinary Unit and $0.689 per Pre-Funded Unit.
- Placement Agent Fees: 7% cash fee plus 0.5% non-accountable expenses allowance, plus up to $125,000 in reimbursable costs.
- Warrant Terms: Series A Warrants exercisable at $0.69 (subject to reset); Series B Warrants exercisable at $1.173 with a "zero price exercise" option.
- Operating Metrics: The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the successful capital raise of $15 million, closing on June 27, 2025. This represents a significant increase in equity capital compared to the prior period, though specific comparative financial statements are not included in this filing.
Guidance, Outlook, and Risks
- Use of Proceeds: Net proceeds will fund capital expenditures, operating capacity, working capital, general corporate purposes, purchasing warehouses, overseas business expansion, and potential mergers and acquisitions.
- Management Discretion: Management retains discretion to allocate funds based on expansion progress and changing business needs.
- Lock-Up Provisions: The Company agreed not to issue Ordinary Shares or equivalents for 60 days and not to enter Variable Rate Transactions for 90 days following the agreement date.
- Dilution Risk: The "zero price exercise" option on Series B Warrants could result in the issuance of up to 322,113,130 additional shares if the share price falls to the floor price of $0.1395.
Investor Verification Checklist
- Verify the actual net proceeds received after deducting the 7.5% placement fees and legal expenses.
- Confirm the current trading price of Ordinary Shares to assess the likelihood of Series B Warrant "zero price exercise" dilution.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants and exceptions to the lock-up period.
- Monitor future filings for the allocation of proceeds toward specific capital expenditures or acquisitions.